Lantheus Enters Strategic Collaboration with Cerevast for knowledge New Eye Care application the usage of Microbubbles

NORTH BILLERICA, Mass.--(enterprise WIRE)--Apr 2, 2019--Lantheus Holdings, Inc. (the “company”) (NASDAQ: LNTH), guardian business of Lantheus clinical Imaging, Inc. (“LMI”), a world leader in the development, manufacture and commercialization of ingenious diagnostic imaging brokers and products, these days introduced it has entered into a strategic collaboration with Cerevast medical, Inc. (“Cerevast”) for the remedy of retinal vein occlusion (RVO), probably the most normal causes of imaginative and prescient loss international. This collaboration matches squarely into Lantheus’ increase method to identify new applications for its microbubble franchise and expand into new disease areas, equivalent to ocular illnesses.

below a building and business give agreement, Lantheus’ microbubble will be utilized in aggregate with Cerevast’s ocular ultrasound equipment to goal enhancing blood stream in occluded retinal veins within the eye. Cerevast’s RVO know-how will mix intravenous administration of Lantheus’ microbubbles with non-invasive ultrasound delivered throughout the closed eyelid. via treating the underlying cause of the ailment as hostile to the symptoms, this remedy has the potential to reduce or eliminate the need for chronic upkeep therapy and increase the nice of existence for those sufferers inflicted through RVO. Cerevast’s RVO know-how is expected to enter a phase 2B clinical trial within the 2nd half of 2019. Cerevast has acquired an investigational gadget exemption (IDE) from the U.S. FDA, which makes it possible for its investigational ocular ultrasound equipment for use in a clinical study to be able to bring together safeguard and effectiveness information.  If authorized, the RVO technology may well be commercialized in 2023.

“we are excited to collaborate with Cerevast to extend our microbubble franchise into a new medicine modality that has the abilities to help millions of patients plagued by RVO,” referred to Mary Anne Heino, President and Chief executive Officer of Lantheus. “Our collaboration leverages both businesses’ strengths as leaders featuring novel, first-in-category solutions to the healthcare neighborhood. as the use of microbubbles in diagnostic and therapeutic functions beneficial properties more hobby within the global market, our collaboration with Cerevast demonstrates our commitment to have Lantheus’ microbubble franchise lead that evolution.”

“we're delighted to enter into this collaboration with Lantheus,” spoke of Bradford Zakes, President and Chief govt Officer of Cerevast. “Lantheus’ abilities within the box of microbubbles combined with Cerevast’s novel and proprietary ultrasound know-how form the basis for an extended-time period, a hit collaboration. We seem to be forward to working with Lantheus to are trying to improve this promising know-how to market and aid sufferers that suffer from the debilitating disease of RVO.”

RVO is a chronic eye condition that happens when blood clots kind in the small veins that raise blood far from the retina. This situation impacts approximately 16.4 million people global, and that inhabitants is becoming due to growing old, leading to 1.1 million new circumstances every 12 months. 1-three Left untreated, sufferers with RVO undergo a progressive, deterioration of vision that may greatly impair great of lifestyles and might cause permanent blindness. a brand new remedy that addresses the actual reason behind RVO might also doubtlessly get rid of the want for lengthy-time period renovation therapy. 1

“Microbubble-mediated ultrasound represents a novel method to the medication of RVO that may address the physical explanation for the ailment, stated Dr. Mark Humayun, M.D., Ph.D., biomedical engineer, researcher and recognized thought leader in the container of ophthalmology. “Restoring blood move to occluded veins offers the potential to reduce the need for long term intra-ocular injections and improve vision in sufferers stricken with this disorder. I seem to be ahead to the persisted development of this entertaining potential therapy.”

As a part of the agreement, Cerevast can be accountable for regulatory filings and approvals within the U.S., Europe and China, as well as commercialization of the RVO technology. Cerevast can have exclusive rights to commercialize Lantheus’ microbubble and activation device as a part of its RVO expertise.

Lantheus will give its microbubble vials and its activation instruments at a predetermined switch price. moreover, Lantheus will acquire royalties on sales of the RVO technology after regulatory approval.

About Lantheus Holdings, Inc. and Lantheus medical Imaging, Inc.

Lantheus Holdings, Inc. is the mother or father enterprise of LMI, a worldwide chief within the construction, manufacture and commercialization of resourceful diagnostic imaging agents and products. The enterprise is headquartered in North Billerica, Massachusetts with workplaces in Puerto Rico and Canada. For greater advice, consult with www.lantheus.com.

About Cerevast scientific, Inc.

Cerevast clinical, Inc. is a medical-stage scientific machine business based mostly in Bothell, Washington, united states of america. Leveraging its core talents in the fields of ultrasound and microsphere applied sciences, Cerevast is committed to constructing novel, first-in-classification therapeutic options to repair health and enhance the nice of lifestyles for sufferers that undergo from foremost illnesses. The enterprise’s lead clinical stage classes are for the treatment of ischemic stroke and retinal vein occlusion, two devastating ailments with restricted medication options that effect hundreds of thousands of sufferers international each and every yr. For greater suggestions, consult with www.cerevast.com.

secure Harbor for forward-looking and Cautionary Statements

This press liberate consists of “ahead-searching statements” as described under U.S. federal securities laws, together with statements about our future outlook. ahead-looking statements may be recognized by their use of phrases such as anticipate, accept as true with, confident, may, has the competencies to, estimate, expect, intend, may also, plan, predict, undertaking, goal, will and different identical terms. Such forward-searching statements are subject to dangers and uncertainties that might trigger precise results to materially vary from these described in the ahead-searching statements. Readers are recommended not to location undue reliance on the forward-looking statements contained herein, which speak best as of the date hereof. The enterprise undertakes no duty to publicly update any forward-looking commentary, whether as a result of new advice, future tendencies or otherwise, apart from as could be required with the aid of legislations. dangers and uncertaint ies that could cause our genuine results to materially range from those described within the forward-searching statements are discussed in our filings with the Securities and trade commission (including those described within the chance elements area in our Annual reviews on form 10-ok and our Quarterly stories on form 10-Q).

1 Cerevast

2 American Academy of Ophthalmology (AAO) 2010

three Laouri M, Chen E, Looman M, Gallagher M. The burden of ailment of retinal vein occlusion: evaluation of the literature. Eye. 2011;25(eight):981-988. doi:10.1038/eye.2011.ninety two.

View supply edition on businesswire.com:https://www.businesswire.com/news/domestic/20190402005333/en/

CONTACT: Media:

Meara Murphy

Director, company Communications

978-671-8508Investors:

Mark Kinarney

Director, Investor relations

978-671-8842

keyword: u.s. NORTH the usa MASSACHUSETTS

business key phrase: fitness BIOTECHNOLOGY clinical TRIALS medical instruments OPTICAL

supply: Lantheus Holdings, Inc.

Copyright business Wire 2019.

PUB: 04/02/2019 08:00 AM/DISC: 04/02/2019 08:00 AM

http://www.businesswire.com/information/domestic/20190402005333/en

Copyright business Wire 2019.

© 2019 The associated Press. All rights reserved. This cloth might also now not be published, broadcast, rewritten or redistributed.